HER2-positive breast cancers, historically associated with poor outcomes, have seen dramatic improvements in oncologic outcomes with targeted therapies such as trastuzumab [35], pertuzumab [36], and T-DM1 [37], which have transformed HER2 overexpression into a therapeutic vulnerability. This evidence concerns the gene ERBB2 and breast carcinoma.